Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This study is a Phase II randomized, open label, controlled, multicenter study to access the effects and tolerability of fluzoparib combined with apatinib versus fluzoparib monotherapy for maintenance treatment in platinum-sensitive relapsed ovarian carcinoma (including patients previous treated with a PARP inhibitor).
Epistemonikos ID: fc7360f3d0de607bb11f8060140523049bafc702
First added on: May 13, 2024